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Abstract G2 and S phase-expressed-1 (GTSE1) was
recently reported to upregulate in several types of hu-
man cancer, based on negatively regulate p53 expres-
sion. However, its expression and functional roles in
hepatocellular carcinoma (HCC) remain unknown. In
this study, GTSE1 was observed to be highly expressed
in HCC specimens and cell lines both at messenger
RNA (mRNA) and protein levels. Furthermore, high
GTSE1 expression was positively associated with tumor
size, venous invasion, advanced tumor stage, and short
overall survival. Moreover, we generated stable GTSE1
knockdown HCC cell lines to explore the effects of
GTSE1 silencing on the growth and invasion of HCC
in vitro. In determining the pathway through which
GTSE1 regulated cell proliferation and invasion,
GTSE1 silencing was found to inhibit AKT phosphor-
ylation and downregulated cell cycle-related protein. In
addition, GTSE1 downregulation decreased the growth
of xenografts. In conclusion, these results indicated for
the first time that overexpression of GTSE1 was in-
volved in the progress of HCC, enhancing proliferation
and promoting cell invasion in HCC cells.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most ma-
lignant cancers all over the world, with the third cause of
cancermortality (Poon 2011; Liu et al. 2015). A number of
risk factors have been shown to drive this process, includ-
ing hepatitis virus infections, non-alcoholic fatty liver dis-
eases, and alcoholic liver diseases (Cavazza et al. 2009).
Although HCC diagnosed at early stage is curable through
surgical resection, patients are often diagnosed with HCC
at advanced stage. Molecular biological study of HCC is
thus required to develop novel therapeutic approaches.
G2 and S phase-expressed-1 (GTSE1), located in
chromosome 22q13.2-q13.3, specifically expressed dur-
ing S and G2 phases of the cell cycle (Utrera et al. 1998;
Monte et al. 2000). GTSE1 has been previously
Cell Biol Toxicol (2016) 32:263–274
DOI 10.1007/s10565-016-9327-z
Lei Guo and Shumin Zhang contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10565-016-9327-z) contains supplementary
material, which is available to authorized users.
L. Guo : B. Zhang :W. Chen :X. Li :W. Zhang :
C. Zhou : J. Zhang :N. Ren :Q. Ye
Liver Cancer Institute and Zhongshan Hospital, Fudan University,
Shanghai 200032, China
L. Guo : B. Zhang :W. Chen :X. Li :W. Zhang :
C. Zhou : J. Zhang :N. Ren :Q. Ye
Key Laboratory of Carcinogenesis and Cancer Invasion, Fundan
University, Ministry of Education, Shanghai 200032, China
S. Zhang
Department of Radiation Oncology, Zhongshan Hospital, Fudan
University, Shanghai 200032, China
N. Ren (*) :Q. Ye (*)
Department of Liver Surgery, Zhongshan Hospital, Fudan
University, No.180 Fenglin Road, Shanghai 200032, China
e-mail: ren.ning@zs-hospital.sh.cn
e-mail: ye.qinghai@zs-hospital.sh.cn
interacted with p53 and relocalized p53 to the cytoplasm
to undergo degradation (Monte et al. 2004). Further study
indicated that overexpression of GTSE1 was frequently
detected in human cancers. It has been shown that am-
plification of GTSE1 gene has been found in lung cancer,
and high GTSE1 expression was associated with the
histological types (Tian et al. 2011). Significantly in-
creased GTSE1 expression has also been demonstrated
in myeloma cells after cisplatin treatment (Spanswick et
al. 2012). It has also been reported that upregulation of
GTSE1 in gastric cancer contributed to inhibited cisplatin
sensitivity via p53 apoptotic signaling (Subhash et al.
2015). However, the role of GTSE1 in the development
of HCC in vitro and in vivo has not yet been elucidated.
In the current study, we show that GTSE1 was
overexpressed and correlated with tumor invasion and
worse outcome in HCC. Downregulation of GTSE1
inhibited the growth of HCC cells via the inactivation




The 76 pairs of HCC specimens and paired non-
cancerous specimens were obtained from surgical resec-
tions at the Liver Cancer Institute, Zhongshan Hospital,
Fudan University between May 2006 and December
2006. No patients have received systemic or local treat-
ment before operation. Tumor stage was determined
according to the sixth edition of the American Joint
Committee on Cancer tumor-node-metastasis (TNM)
staging system. Informed consent was obtained from all
patients. The HCC tissues enrolled were approved by the
Clinical Research Ethics Board of Zhongshan Hospital
affiliated to Fudan University and were performed in
accordance with the Declaration of Helsinki guidelines.
Cell lines
The HCC cell lines (SMMC-7721, Huh7, MHCC97H,
and MHCCLM3), a normal hepatocyte cell line (L02),
and the human embryonic kidney 293T cells were con-
served and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (HyClone, Logan, UT, USA) supple-
mented with 10% fetal bovine serum (Invitrogen, Carls-
bad, CA, USA), 100 units/ml penicillin, and 100 μg/ml
streptomycin. All cells were cultured at 37 °C humidi-
fied incubator under an atmosphere of 5 % CO2 in air.
RNA extraction and real-time quantitative
reverse-transcription polymerase chain reaction
Total RNA was extracted from HCC tissues and cells
using Trizol Reagent (Invitrogen) following the manu-
facturer’s instructions. One microgram total RNA was
converted to first-strand cDNA using the PrimeScript
RT reagent kit (TaKaRa, Japan). Real-time quantitative
reverse-transcription polymerase chain reaction (qRT-
PCR) was performed with the Realtime PCR Master
Mix (Toyobo, Osaka, Japan) according to the manufac-
turers’ instructions by an ABI 7900HT real-time PCR
system (Applied Biosystems, Foster City, CA, USA),
following temperature profiles: 1 cycle at 95 °C (2 min),
40 cycles of denaturation at 95 °C (30 s), and annealing
at 60 °C (1 min). The primer sequences used were as
follows: 5′-CCACCGGGATGTTCTCCCT-3′ (forward
primer) and 5′-TTCAGCCCCAACTTGTTTGGA-3′
(reward primer) for GTSE1; 5 ′-ACCCAGAA
GACTGTGGATGG-3′ (forward primer) and 5′-
CAGTGAGCTTCCCGTTCAG-3′ (reward primer) for
GAPDH. Then, the 2−ΔΔCT method was used to de-
termine the relative gene expression levels, and each
experiment was repeated at least three times.
GAPDH was used as an internal control.
Plasmids and transfection
Short hairpin RNA (shRNA) against the human
GTSE1 was designed and synthesized by the Shang-
hai Invitrogen, China. The optimal sequence of
shRNA targeting GTSE1 (5 ′-CCGGGCCTAC
TCCTACAAATCAATTCTCGAGAATTGATTTGT
AGGAGTAGGCTTTTTG-3′ (forward primer) and
5 ′-AATTCAAAAAGCCTACTCCTACAAATC
AATTCTCGAGAATTGATTTGTAGGAGTAGGC3′
(reward primer) was then cloned into the lentiviral
plasmid pLKO.1-TRC Cloning Vector. Lentivirus
productions were produced as described previously
(Dong et al. 2016). To generate stable shRNA
knockdown cells, targeted HCC cells were added
with viral supernatant and 8 μg/ml polybrene
(Sigma-Aldrich, St Louis, MO, USA) for 24 h. Then
the cells were treated with 2 μg/ml puromycin
(Sigma) for 48 h.
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Proliferation assays
Cell viability was assessed by CCK-8 (Dojindo, Kuma-
moto, Japan) assay. Cells (4×103 /well) were seeded in
96-well plate. Ten microliters CCK-8 was added to each
well at 72 and 96 h. Absorbance was measured at
450 nm after incubating for another 2 h at 37°.
Colony formation assay
Cells were seeded into six-well plates at a density of 800
per well and incubated at 37 °C and at an atmosphere of
5 % CO2 for 14 days. Cells were fixed with methanol at
−20 °C for 5 min and stained with 0.5 % crystal violet
for 30 min. Only clearly visible colonies (more than 50
cells) were counted under a light microscope.
Flow cytometric analysis of cell cycle analysis and cell
apoptosis
For the cell cycle analysis, cells were harvested, washed
with phosphate-buffered saline, and then fixed in 70 %
ice-cold ethanol at 4 °C overnight. Cells were treated
with RNase (final concentration 0.2 mg/ml) and stained
with propidium iodide (final concentration 10 μg/ml) in
the dark, following detection with a FACSCalibur
Cytofluorimeter (Becton-Dickinson) as previously de-
scribed (Wong et al. 2014).
For the cell apoptosis analysis, cells were harvested
and stained with the Annexin V-FITC Apoptosis Detec-
tion Kit (Sigma-Aldrich) following the manufacturer’s
protocol. Apoptosis was measured and analyzed as pre-
viously described (Zhu et al. 2016). All experiments
were performed at least three times.
Migration and invasion assay
Boyden chamber assay with or without coated
Matrigel (BD Biosciences, Sparks, MD, USA) was
used to perform the cell migration or invasion anal-
ysis, respectively. The cells (4 × 105 /well) were
suspended in 200 μl of serum-free medium and
seeded into the upper chamber of the 8-μm pore
inserts (Corning Inc., NY, USA). Six hundred-
microliter medium containing 10 % fetal bovine
serums was added to the lower chamber as a
chemoattractant. Following 24-h incubation for mi-
gration and 48-h incubation for invasion at 37 °C,
the cells on the upper surface of the filter were
scraped off with a cotton swab, and the migrated
or invaded cells on the lower surface were fixed and
stained with 1 % crystal violet for 15 min. The
number of migrated or invaded cells per field was
determined by calculating six random fields. All
experiments were performed in triplicate wells and
repeated three times.
Immunohistochemistry
Immunohistochemical staining was performed as previ-
ously described with a Dako Dako REAL™ Detection
System (Zhu et al. 2013). In brief, 4-μm formalin-fixed
paraffin sections were cut. After the antigen retrieval in
citrate buffer, sections were blocked with 5 % normal
goat serum at room temperature and stained with anti-
bodies against GTSE1 (Proteintech Group, Inc., Chica-
go, IL, USA), followed by incubation with goat anti-
Rabbit IgG-biotinylated secondary antibodies
(Dakopatts, Glostrup, Denmark), and visualized by
standard avidin-biotinylated peroxidase complex meth-
od. Staining intensity was evaluated by two investiga-
tors who were unaware of clinicopathological features
of the patients. Dark brown staining was defined as
positive, and no staining was defined as negative. The
percentage of positive cells and the intensity of immu-
nostaining were used to produce a weighted score for
each case.
Western blotting analysis
Whole-cell extracts were prepared as described pre-
viously (Liu et al. 2013). In brief, equivalent
amounts of protein (50 μg) were separated by sodi-
um dodecyl-sulfate-polyacrylamide gel electropho-
resis (10 %) and transferred to nitrocellulose mem-
brane (Bio-Rad, Hercules, CA). The membranes
were subsequently incubated with the following pri-
mary antibodies: GTSE1 (Proteintech Group, Inc),
AKT, phospho-AKT (Ser473), and cyclin B1 from
CST (Cell Signaling Technology, Beverly, MA,
USA), BCL-2 and Bax from Abcam (AbCam, Cam-
bridge, MA, USA), and GAPDH (CST) was used as
a loading control. The blots were visualized with a
horseradish peroxidase-conjugated secondary anti-
body (Kangchen, Shanghai, China) and an enhanced
chemiluminescence kit (Millipore, Bedford, MA).
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In vivo experimental tumorigenesis assay
All of the animal care and experimental procedures were
performed in accordance with the Laboratory Animal
Care Guidelines and approved by the Animal Care and
Use Committee of Zhongshan Hospital, Fudan
University.
Four-week-old male BALB/c nude mice were pur-
chased from the Shanghai Experimental Animal Center
and subcutaneously injected with 1× 107 LM3 cells
transfected with negative control (SCR) or GTSE1-
SH. The tumor dimensions were measured with vernier
calipers every 1 week. Mice were sacrificed 5 weeks
after the subcutaneous injection, following the xeno-
grafts weights were immediately measured.
Statistical analysis
All experiments were performed in triplicate in three
independent experiments. Data were expressed as
means ± standard deviation (SD). Statistical analyses
were performed using SPSS 16.0 (IBM, Armonk, NY,
USA). Pearson’s chi-square test was performed to de-
termine the relationship between GTSE1 expression and
Fig. 1 Upregulation of GTSE1 in
HCC. a qRT-PCR analysis of
mRNA levels of GTSE1 in 76
paired of HCC tissues and adja-
cent non-cancerous tissues (NC
tissues). b The mRNA level of
GTSE1 was quantified in four
HCC cells and a non-malignant
liver cell (L02). c The protein
level of GTSE1 was determined
in four HCC cells and a non-
malignant liver cell (LO2) by
western blot assays. GAPDH was
used as an internal control.
*P< 0.05, **P< 0.01
Fig. 2 High GTSE1 expression
was associated with poor
prognosis in HCC. a
Immunohistochemistry of
GTSE1 protein expression in
non-cancerous tissues and HCC
specimens. GTSE1-negative
staining in normal tissue is shown
in the left, whereas strong
GTSE1-positive staining in HCC
is presented in the right. b
Kaplan–Meier survival curve was
performed to reveal that patients
with high GTSE1 expression suf-
fered the worse outcome
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clinical parameters. Kaplan-Meier method was used to
assess survival curves. A paired t test (two tails) was
used for statistical analyses between two groups.
Results
GTSE1 is aberrantly overexpressed in HCC cell lines
and cancerous tissues
To investigate the expression of GTSE1 in HCC tumor
samples, qRT-PCR was utilized to detect the messenger
RNA (mRNA) levels of GTSE1 in HCC tumor samples
and corresponding adjacent non-cancerous tissues. As
shown in Fig. 1a, GTSE1 expression was significantly
higher in 76 paired HCC tissues compared with
paraneoplastic non-cancerous tissues. Furthermore, we
measured the mRNA levels of GTSE1 in HCC cells.
Interestingly, we found that GTSE1 expression was
remarkably higher in HCC cells compared with non-
malignant liver cells (L02) (Fig. 1b). Consistently,
GTSE1 protein expression was increased in HCC cells
compared with LO2 as detected by western blot, espe-
cial in 97H and LM3 (Fig. 1c). Hence, our data sug-
gested that GTSE1 expression is upregulated in HCC.
High GTSE1 expression is associated with tumor size,
venous invasion, and advanced tumor stage and predicts
poor prognosis
To further confirm GTSE1 expression, immunohisto-
chemistry was performed in HCC tissues and
Table 1 Associations between GTSE1 protein expression levels and clinicopathologic variables of HCC patients
Clinicopathologic variables All cases (n= 76) GTSE1 expression P value
High (39) Low (37)
Gender
Male 67 34 33 1.00
Female 9 5 4
Age, years
≤60 44 24 20 0.6426
>60 32 15 17
Liver cirrhosis
Absent 42 23 19 0.6448
Present 34 16 18
Tumor encapsulation
Absent 36 22 14 0.1222
Present 48 20 28
Tumor size (cm)
≤5 34 11 23 0.0053
>5 42 28 14
Tumor multiplicity
Single 53 26 27 0.6220
Multiple 23 13 10
Venous invasion
Absent 44 17 27 0.0115
Present 32 22 10
TNM stage
I–II 41 16 25 0.0203
III 35 23 12
P values were calculated by Fisher’s exact test
TNM tumor-node-metastasis
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paraneoplastic non-cancerous tissues. GTSE1 staining
was mainly observed in the cytoplasm of the cells as
shown in Fig. 2a. A majority (56/76, 73.7 %) of HCC
samples were found to be positive for GTSE1. In con-
trast, only 22.4 % (17/76) non-cancerous samples were
positive for GTSE1. The difference between tumor and
non-cancerous specimens was highly significant
(P<0.001). The relationship between clinicopathologi-
cal parameters and GTSE1 expression is summarized in
Table 1. High GTSE1 expression positively associated
with clinicopathological parameters like tumor size
(P=0.0053), venous invasion (P=0.0115), and tumor
grade (P=0.0203), whereas other clinic-pathological
characteristics have been shown no correlation. In addi-
tion, the Kaplan-Meier survival curves were performed
to determine the correlation between GTSE1 expression
and HCC patient survival. We found a significantly
shorter overall survival time (41 months) in patients
with higher GTSE1 expression than those with lower
GTSE1 level (59 months), as shown in Fig. 2b. Univar-
iate analysis showed that GTSE1, tumor size, vascular
invasion, and tumor-node-metastasis stage were signif-
icantly associated with OS in HCC patients (Table 2). In
addition, multivariate analysis showed that GTSE1 was
an independent prognostic indicator for OS (Table 3).
GTSE1 knockdown suppresses tumor cell proliferation,
arrested cell cycle, and induced cell apoptosis
Since GTSE1 overexpression was observed in HCC
tissues and cells, our next question is whether GTSE1
had a direct functional role in facilitating tumor growth
in HCC. Stable knockdown of GTSE1 in 97H and LM3
cells was constructed via lentiviral infection by and
confirmed by western blotting analysis (Fig. 3a). Cell
proliferation assay indicated that GTSE1 silencing
Table 2 Univariate analyses of factors associated with overall survival
Variable Overall survival
Hazard ratio (95 % CI) P value
Gender (male vs. female) 2.046 (0.632–6.621) 0.232
Age, years (>52 vs. ≤52) 1.106 (0.613–1.996) 0.738
Liver cirrhosis (yes vs. no) 1.231 (0.685–2.213) 0.488
Tumor encapsulation (none vs. complete) 1.881 (1.019–3.474) 0.043
Tumor size (cm; >5 vs. ≤5) 2.604 (1.338–5.065) 0.005
Tumor number (multiple vs. single) 2.040 (1.134–4.026) 0.057
Vascular invasion (yes vs. no) 2.043 (1.423–3.883) 0.017
TNM stage (II/III vs. I) 3.236 (1.636–6.403) 0.001
GTSE1 (high vs. low) 2.609 (1.394–4.883) 0.003
Univariate analysis, Cox proportional hazard regression model
95 % CI 95 % confidence interval, TNM tumor-node-metastasis
Table 3 Multivariate analyses of factors associated with overall survival
Variable Overall survival
Hazard ratio (95 % CI) P value
GTSE1 (high vs. low) 2.388 (1.193–4.783) 0.014
Tumor encapsulation (none vs. complete) 1.641 (0.716–3.757) 0.242
Tumor size (cm; >5 vs. ≤5) 1.480 (0.607–3.607) 0.389
Vascular invasion (yes vs. no) 1.066 (0.448–2.533) 0.885
Mutivariate analysis, Cox proportional hazards regression model
95 % CI 95 % confidence interval
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significantly inhibited cell proliferation both in 97H and
LM3 cells (P<0.01, Fig. 3b). Colony formation assay
also suggested that GTSE1 knockdown significantly
reduced the number and size of cell colonies formed
compared with the SCR group (Fig. 3c). Furthermore,
flow cytometric analysis was performed to evaluate
whether the effect of GTSE1 on proliferation of HCC
cells affected cell-cycle progression and apoptosis. Our
data showed that downregulation of GTSE1 expression
leads to a significant increase of G0/G1 phase compared
with negative control (P<0.01, Fig. 3d). Apoptotic
assay also showed that knockdown GTSE1 could obvi-
ously promote cell apoptosis (P<0.01, Fig. 3e). These
findings indicated that GTSE1 might play as an onco-
gene in HCC.
GTSE1 knockdown inhibited cell migration
and invasion
As clinical data shown, high GTSE1 expression was
associated with venous invasion. Thus, GTSE1 may
play an important role in HCC cell migration and inva-
sion that is very important for tumor metastasis.
Transwell assays were used to explore the effect of
GTSE1 on the motile and invasive phenotype of HCC
cells. Migration and invasion were significantly reduced
in GTSE1 knock downed 97H cells compared with
control cells (P<0.01, Fig. 4a). The same results were
also observed by using another HCC cell line, LM3
(P<0.01, Fig. 4b).
Next, we sought to determine how GTSE1 exerted
these biological effects by characterizing its effect on
known functional molecule and signaling pathways.
Accumulated reports have shown that the PI3K/AKT
and ERK/MAPK are the signaling pathways for tumor
growth and invasion (Mishra et al. 2012; Sui et al.
2015). Therefore, we assessed the effect of GTSE1 on
the levels of phosphorylation of AKT and ERK. Our
results showed that GTSE1 silencing resulted in a de-
crease of phosphorylation of AKT and ERK and a
downstream target BCL-2, MMP-2, and MMP-9, an
increase of Bax and p53 both in 97H and LM3 cells
(Fig. 4c). Compared with negative control cells, GTSE1
downregulation in 97H and LM3 cells decreased cyclin
B1 protein expression (Fig. 4c), a crucial regulatory
protein in G2/M phase. These findings suggested that
GTSE1 silencing inhibits the proliferation and invasion
of HCC cells may be mediated by affecting the phos-
phorylation level of AKT and the expression of BCL-2,
Bax, and cyclin B1.
Knockdown of GTSE1 suppresses tumor growth in vivo
Given that GTSE1 silencing impaired the growth of
HCC cells in vitro, we determined whether GTSE1
silencing could affect tumorigenicity in vivo. We
injected LM3 cells transfected with either SCR or
GTSE1silencing into nude mice. Consistent with results
in vitro, tumor growth in GTSE1 silencing group was
obviously slower than that in the SCR group (Fig. 5a, b).
The average tumor weight in GTSE1 silencing group
was markedly lower than that in the SCR group
(Fig. 5c). In addition, transplantation tumor specimens
were resected and stained with Ki67 by immunohisto-
chemistry. The result showed that the expression of
Ki67 was reduced in the GTSE1 knockdown group,
which revealed a low cell proliferation compared with
the SCR group in vitro (Fig. 5d). These data support a
role for GTSE1 upregulation in promoting the formation
and growth of tumor xenografts in vivo.
Discussion
The abnormal expression of genes has been reported in
many types of cancer, and a number of genes have been
explored in the process of cancer development (Zhu
et al. 2013; Cao et al. 2014). In our present study, we
first found that GTSE1 was frequently upregulated in
HCC tissues and cells and the increased GTSE1 expres-
sion was closely related to tumor size, venous invasion,
and advanced stage of HCC. Furthermore, loss of func-
tion assays on GTSE1 indicated that inhibition of
GTSE1 was not only significantly decreased HCC tu-
mor growth in vitro and in vivo but also suppressed the
migration and invasion in vitro. Our results showed that
GTSE1 might play a proto-oncogenic role in HCC
development and may be useful as a therapeutic target
for HCC.
Fig. 3 Silencing of GTSE1 inhibited HCC cell growth. aWestern
blots were performed to confirm GTSE1 stably downregulated in
97H and LM3 cells. b The CCK-8 assay was used to quantify the
relative cell viability at indicated time points. c Representative
pictures of colony formation assay in 97H and LM3 cells
transfected with or without GTSE1. d The ratio of cells at different
cell cycle phases was evaluated by flow cytometric analysis and
quantitative analysis of the different cell cycle phases. e Cell
apoptosis of 97H and LM3 cells transfected with SCR or
GTSE1-SH was assessed by flow cytometric analysis. **P< 0.01
R
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GTSE1, a negative regulator of p53, was a
microtubule-localized protein, and its upregulation con-
tributes to the aggressive behavior of several cancer
types (Tian et al. 2011; Spanswick et al. 2012; Subhash
et al. 2015; D’Errico et al. 2009). Higher GTSE1 ex-
pression is associated with more aggressive phenotypes
in neuroendocrine tumors (Lee et al. 2012). Consistent
with these results, our results demonstrated that GTSE1
was upregulated in HCC tissues and associated with
tumor size, venous invasion, advanced stage, and patient
overall survival. These data strongly indicated that
GTSE1 could play a crucial role in HCC progression.
Furthermore, our current data also showed that GTSE1
knockdown inhibited proliferation, migration, and inva-
sion and induced apoptosis of HCC cells in vitro, which
is consistent with the data on breast cancer (Scolz et al.
2012). Previous studies have also reported that GTSE1
may play a role in the regulation of cell cycle via
promoting p53 localization to the cytoplasm, which is
influencing cell cycle distribution (Monte et al. 2003;
Liu et al. 2010). In both 97H and LM3 cells, knockdown
of GTSE1 resulted in an increase of G0/G1 phase and a
decrease of G2/M phase. Then, the expression of cyclin
b1 and p53 also indicated the alteration of GTSE1 that
regulated the distribution of cell cycle.
In order to understand the contribution of GTSE1 to
HCC progress, it would be of great interest to identify
signaling cascades by which GTSE1 promoted prolifer-
ation and invasion. Previous studies showing that AKT
and ERK were associated with survival pathway and
apoptosis pathway (Bratton et al. 2010; Ding et al.
2015), we then inquired about whether GTSE1 utilized
the same pathway to affect cell growth and invasion. In
this study, knockdown of GTSE1 downregulated phos-
phorylation of AKT, BCL-2, and cyclin B1 but upreg-
ulated Bax, which suggested that GTSE1 contributes to
high aggressive behavior of HCC through its enhancing
effect on AKTsurvival pathway and apoptosis pathway.
Fig. 4 GTSE1 knockdown suppressed cell invasion and regulated
AKT phosphorylation. a Matrigel-uncoated/coated transwell cell
invasion assays of 97H cells transfected with SCR or GTSE1-SH.
bMatrigel-uncoated/coated transwell cell invasion assays of LM3
cells transfected with SCR or GTSE1-SH. cWestern blot detection
of GTSE1, ATK, p-AKT, ERK, p-ERK, BCL-2, Bax, cyclin B1,
p53, MMP-2, and MMP-9 expression in 97H and LM3 cells
transfected with SCR or GTSE1-SH. **P< 0.01
Fig. 5 Knockdown of GTSE1
inhibits the growth of HCC in
vivo. a Representative pictures of
subcutaneous implantation tumor
of LM3 cellsat 5 weeks after
injection were shown. b Tumor
growth curves of subcutaneous
implantation models of LM3 cells
at indicated time points. c Tumor
weights were quantified. Data
were represented as the mean
± SD of three independent
experiments. d Representative
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In summary, our study demonstrated that GTSE1was
overexpressed in HCC at both mRNA and protein levels
and a poor prognostic marker. GTSE1 knockdown was
found to affect cell proliferation, migration, and inva-
sion of HCC cells through dysregulation of AKT, BCL-
2, Bax, and cyclin B1. Further investigation of GTSE1
might provide potentially useful information for devel-
oping biological or pharmacological agents for HCC
patients.
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